UGT1A1*28 Genotypes and Respiratory Disease in Very Preterm Infants: A Cohort Study

Jesper Padkær Petersen, Finn Ebbesen, Mads Vilhelm Hollegaard, Sofia Andersson, David Michael Hougaard, Ole Thorlacius-Ussing, Tine Brink Henriksen

Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark

Abstract

Background: Respiratory disease in the very preterm infant is frequent and often severe. Bilirubin is both a potent neurotoxin and antioxidant, and may have a clinical impact on preterm respiratory disease. The Gilbert genotype, the UGT1A1*28 allele, is the major known genetic cause of variation in bilirubin.

Objectives: To study the association between respiratory disease in the very preterm infant and the UGT1A1*28 allele.

Methods: This is a cohort study of 1,354 very preterm infants (gestational age <32 weeks) born in Jutland, Denmark in 1997–2011. Genotypes were obtained from the Danish Neonatal Screening Biobank, and clinical information was obtained from the databases of two tertiary neonatal intensive care units. Outcomes were the need for surfactant therapy, any need for and duration of supplementary oxygen and bronchopulmonary dysplasia (BPD).

Results: Per UGT1A1*28 allele, odds were increased for any need of supplementary oxygen (odds ratio 1.26; 1.05–1.50) and for BPD (odds ratio 1.71; 1.23–2.39), the need of supplementary oxygen increased by 6.38 days (1.87–10.89), and chance per day of no longer needing supplementary oxygen was reduced (hazard rate 0.84; 0.76–0.93). No effect was observed for need of surfactant treatment (odds ratio 1.08; 0.91–1.28). Hardy-Weinberg equilibrium was unlikely for the cohort (p < 0.012). This could be explained by death prior to genotype sampling. In tests of robustness this failed to explain the primary results.

Conclusions: Compared to the common genotype, UGT1A1*28 genotypes were associated with an increased need of oxygen supplementation and risk of BPD in very preterm newborns.

Introduction

Oxidative stress is thought to be involved in respiratory disease amongst preterm infants, and antioxidants may accordingly be important in its prevention [1, 2].

Bilirubin is neurotoxic, but it is also an antioxidant of possible clinical relevance [3]. The association between bilirubin and respiratory disease in the preterm population has been explored in previous observational studies and as a secondary outcome in an interventional study, with diverging results [4–6]. The challenges in noninterventional studies of bilirubin’s influence on neonatal out-
comes are the possibility of reverse causality and the presence of potential confounding factors. One way of addressing these challenges is by utilizing the genotype of Gilbert-Meulengracht syndrome, the UGT1A1*28 allele [7].

The rate-limiting enzyme in the metabolism of bilirubin is hepatic uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) [8]. In the UGT1A1*28 allele an extra TA pair is inserted in the TATA box of the UGT1A1 gene, reducing the activity of hepatic UGT1A1 by approximately 30% per allele. The allele is the major known genetic cause of variation in plasma bilirubin in adult Western European populations, accounting for approximately 18% of all variations [8–10]. In the term neonatal population, the allele has been associated with accelerated development and duration of hyperbilirubinemia, while the association with crossing of treatment thresholds is uncertain [11–13]. No data exist for the preterm population.

Mendel’s second law states that alleles are inherited randomly at conception. As genotypes are permanent, estimates of the association between UGT1A1*28 genotypes and respiratory outcomes will be unconfounded, and thus the possibility of reverse causality is eliminated [9, 14]. To test the effect of genetically elevated bilirubin, we investigated the association between UGT1A1*28 genotypes and respiratory disease in a cohort of 1,354 very preterm infants.

Subjects and Methods

The study setting was two regions in Jutland, Denmark (1997–2011), with a population of 1.3 million people and some 21,000 live births per year. The study units were the two regional tertiary neonatal intensive care units (NICUs).

In Denmark, the first choice of respiratory support is nasal continuous positive airway pressure, with surfactant provided as rescue treatment to preterm infants with respiratory distress syndrome, according to nationally uniform criteria as described by Verder et al. [15]. During the study period, the two units used supplementary oxygen, targeting saturations at 88–92%.

The neonatal database of the two tertiary NICUs provided data on birth weight, gestational age (best obstetric estimate), date of birth, sex, and hospital records [16]. The database does not hold information on bilirubin measures or phototherapy. The study population was restricted to primary admissions at a study NICU within the first 24 h of life, gestational age <32 weeks, birth weight <2,000 g and no life-threatening malformations. Follow-up ended at first discharge from the tertiary NICU or death.

At birth, Danish citizens are assigned a unique 10-digit civil identity as a continuous covariate (parent born in Africa: no = 0, one = 1, both = 2), sex and year of birth as a categorical covariate (1997–2001, 2002–2006 and 2007–2011). Hardy-Weinberg equilibrium (HWE) was estimated using the ‘hwsnp command’. Spearman’s rank correlation was used to evaluate genotype distributions across four gestational age groups (24–25 weeks, 26–27 weeks, 28–29 weeks and 30–31 weeks).
Death and BPD/discontinuation of supplementary oxygen were competing outcomes, and the majority of infants who died were not in the Biobank. As this could potentially cause immortal person-time bias in our study, we performed two tests of robustness for primary results. Continuous outcomes were re-examined with the use of a time scale of days from 28 days’ postnatal age, the routine day of metabolic screening for very preterm infants in the two NICUs and thus the presumed day of study entry. Furthermore, all analyses were repeated and stratified into infants with a high mortality and low mortality, corresponding to gestational ages of 24–28 weeks and 29–31 weeks. All estimates are reported with 95% confidence intervals.

**Ethics**

The study was approved by the regional Ethics Committees on Human Studies (J.nr. 1-10-72-363-12), the Danish Data Protection Agency (J.nr. 1-16-02-153-12) and the Danish Neonatal Biobank Steering Committee, and conducted according to the principles of the Declaration of Helsinki.

**Results**

The 1,773 infants who fulfilled the criteria for study entry were identified in the neonatal database. For 1,354 of these, the genotype and information on supplementary oxygen were available. A total of 159 infants died before the 28-day postnatal cutoff, and a genotype was not available in 132 of these infants.

The basic characteristics of the study cohort are shown in table 1. Of the 1,354 infants, 920 received supplementary oxygen for at least 1 day. Per UGT1A1*28 allele, we found an unadjusted increase in odds for any need of supplementary oxygen of 24% (OR 1.24; 1.04–1.48), for surfactant treatment of 10% (OR 1.10; 0.93–1.30) and for BPD of 73% (OR 1.73; 1.24–2.40). Per allele, the chance of being weaned off oxygen at any given day was 16% lower (HR 0.84; 0.76–0.93), and the need of supplementary oxygen increased by 6.49 days (2.1–10.9). Adjustment for infant sex, year of birth and African ethnicity had almost no effect on the estimates (table 2). Analyses of genotype as a categorical variable gave similar results (data not shown).

HWE was unlikely for the study cohort (p < 0.012) and also for the part of the cohort in which both parents were born in Denmark (p < 0.005). To assess whether excess mortality prior to dried blood spot sampling may explain some of the deviation from HWE, we used gestational age in four groups as a proxy variable for likelihood of death. UGT1A1*28 genotypes were more frequent in the high mortality/low gestational age stratum, and this distribution was unlikely to be caused by chance (p < 0.005; table 3).

The association between genotype and respiratory support stratified by a proxy variable for high and low mortality (24–28 weeks’ gestational age and 29–31 weeks’ gestational age) was estimated (online suppl. material; see www.karger.com/doi/10.1159/000442042). Overall, the estimates were smaller for all respiratory outcomes in the higher gestational age/low mortality stratum. However, the results between the two strata were quite similar.

Of the original 1,773 infants in the cohort, 1,614 were alive at 28 postnatal days. Data on genotype and oxygen treatment were available in 1,343 of these, of whom 366 received oxygen at that time and thus could enter the analysis of continuous outcomes. Seventeen infants died after 28 days, but in only 3 of these was the dried blood spot missing.

With days from the 28th day after birth as the time frame, we found (unadjusted per allele) that the chance of being weaned from oxygen any day decreased by 14% (HR 0.86; 0.73–1.00) and that 4.98 extra days of extra oxygen was needed (–0.63 to 10.58). Again, adjustment for infant sex, year of birth and African ethnicity left estimates almost unchanged. Fully adjusted estimates for these analyses for UGT1A1*28 heterozygotes and homozygotes are given in table 4. When genotype was considered a categorical variable, the results were similar (data not shown).

### Table 1. Basic clinical characteristics of 1,354 consecutive very preterm infants with UGT1A1 genotyping from the Mid and Northern Regions of Jutland, Denmark, 1996–2011

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boys, %</td>
<td>53</td>
</tr>
<tr>
<td>Gestational age, weeks¹</td>
<td>29 (25–31)</td>
</tr>
<tr>
<td>Birth weight, g¹</td>
<td>1,190 (665–1,815)</td>
</tr>
<tr>
<td>Surfactant treatment, %</td>
<td>40</td>
</tr>
<tr>
<td>Any need of supplementary oxygen, %</td>
<td>68</td>
</tr>
<tr>
<td>Duration of supplementary oxygen treatment, days¹</td>
<td>8 (0–75)</td>
</tr>
<tr>
<td>BPD, %</td>
<td>7</td>
</tr>
<tr>
<td>African (none/1 parent/both parents), n</td>
<td>1,318/14/22</td>
</tr>
</tbody>
</table>

BPD is defined as the need of supplementary oxygen at 36 weeks’ postmenstrual age. ¹ Data are presented as medians (with 5–95 percentile range).

---

Boys, % 53
Gestational age, weeks¹ 29 (25–31)
Birth weight, g¹ 1,190 (665–1,815)
Surfactant treatment, % 40
Any need of supplementary oxygen, % 68
Duration of supplementary oxygen treatment, days¹ 8 (0–75)
BPD, % 7
African (none/1 parent/both parents), n 1,318/14/22

BPD is defined as the need of supplementary oxygen at 36 weeks’ postmenstrual age. ¹ Data are presented as medians (with 5–95 percentile range).
Key Results

In this study, we examined the association between UGT1A*28 genotypes and respiratory morbidity in a cohort of very preterm children. We found that UGT1A*28 genotypes were associated with increased odds for any need of supplementary oxygen, a prolonged need of supplementary oxygen and an increased risk of BPD in preterm survivors. Preterm infants with UGT1A*28 genotypes had the same need for surfactant treatment as those with the common genotype.

HWE was unlikely for the cohort. This prompted a sensitivity analysis whereby we found that UGT1A*28 genotypes were more prevalent in the extremely preterm infants than among the less preterm, the increased prevalence seemingly being associated with death prior to genotype sampling. In two tests of robustness, this association did not explain the primary estimates.

Table 2. The association between UGT1A*28 genotypes and respiratory morbidity for 1,354 very preterm infants

<table>
<thead>
<tr>
<th></th>
<th>Surfactant treatment, OR (95% CI)</th>
<th>Any need of oxygen, OR (95% CI)</th>
<th>Cessation of supplementary oxygen, HR (95% CI)</th>
<th>Duration of oxygen treatment, difference days (95% CI)</th>
<th>BPD, OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>UGT1A*28 heterozygous</td>
<td>1.08 (0.91–1.28)</td>
<td>1.25 (1.05–1.50)</td>
<td>0.84 (0.76–0.93)</td>
<td>6.38 (1.87–10.89)</td>
<td>1.71 (1.23–2.39)</td>
</tr>
<tr>
<td>UGT1A*28 homozygous</td>
<td>1.17 (0.83–1.64)</td>
<td>1.57 (1.10–2.24)</td>
<td>0.71 (0.58–0.87)</td>
<td>12.75 (3.73–21.78)</td>
<td>2.93 (1.51–5.70)</td>
</tr>
</tbody>
</table>

All analyses were adjusted for sex, birth year and African race. OR were estimated by conditional logistic regression, HR by Cox regression analysis and numeric difference in days with oxygen by generalized linear methods with pseudo values. BPD is defined as the need of supplementary oxygen at 36 weeks' postmenstrual age.

Table 3. Distribution of UGT1A*28 genotypes and neonatal mortality on 4 gestational age strata for a cohort of very preterm infants

<table>
<thead>
<tr>
<th>Gestational age, weeks</th>
<th>Common genotype, % (n)</th>
<th>UGT1A*28 heterozygotes, % (n)</th>
<th>UGT1A*28 homozygotes, % (n)</th>
<th>Mortality, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>24–25</td>
<td>41.7 (53)</td>
<td>45.7 (58)</td>
<td>12.6 (16)</td>
<td>38.3</td>
</tr>
<tr>
<td>26–27</td>
<td>43.5 (128)</td>
<td>42.2 (124)</td>
<td>14.3 (42)</td>
<td>14.9</td>
</tr>
<tr>
<td>28–29</td>
<td>51.3 (210)</td>
<td>38.1 (156)</td>
<td>10.5 (43)</td>
<td>5.0</td>
</tr>
<tr>
<td>30–31</td>
<td>52.2 (282)</td>
<td>38.5 (208)</td>
<td>9.3 (50)</td>
<td>1.8</td>
</tr>
</tbody>
</table>

Genotypes are given for the 1,354 infants in the study cohort. Neonatal mortality rates are reported for all the 1,773 infants who would have been in the cohort had dried blood spot samples been available – due to timing of sampling 83% were missing for children who died prior to 28 days' postnatal age.

Table 4. Estimates of association between UGT1A*28 genotypes and time with supplementary oxygen ≥28 days after birth for 1,343 preterm infants, born at 24–31 weeks' gestational age and still alive 28 days after birth

<table>
<thead>
<tr>
<th></th>
<th>Cessation of supplementary oxygen, HR (95% CI)</th>
<th>Duration of oxygen treatment, difference days (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common genotype</td>
<td>Ref.</td>
<td>Ref.</td>
</tr>
<tr>
<td>UGT1A*28 heterozygotes</td>
<td>0.84 (0.71 to 1.00)</td>
<td>5.28 (–0.18 to 10.73)</td>
</tr>
<tr>
<td>UGT1A*28 homozygotes</td>
<td>0.70 (0.50 to 0.99)</td>
<td>10.55 (–0.36 to 21.46)</td>
</tr>
</tbody>
</table>

All analyses were adjusted for birth year, sex and African race. HR were estimated by Cox regression and numeric difference in days with oxygen by generalized linear methods with pseudo values.

Discussion

Key Results

In this study, we examined the association between UGT1A*28 genotypes and respiratory morbidity in a cohort of very preterm children. We found that UGT1A*28 genotypes were associated with increased odds for any need of supplementary oxygen, a prolonged need of supplementary oxygen and an increased risk of BPD in preterm survivors. Preterm infants with UGT1A*28 genotypes had the same need for surfactant treatment as those with the common genotype.

HWE was unlikely for the cohort. This prompted a sensitivity analysis whereby we found that UGT1A*28 genotypes were more prevalent in the extremely preterm infants than among the less preterm, the increased prevalence seemingly being associated with death prior to genotype sampling. In two tests of robustness, this association did not explain the primary estimates.
Strengths and Limitations

Strengths

A major strength of our study is the availability of clinical data and genotypes covering more than a decade for a well-defined population. By combining the clinical information from two tertiary NICUs serving a specific geographical area with the biological data at the Danish Neonatal Screening Biobank, we were able to study the association between UGT1A1*28 genotypes and respiratory morbidity for a large cohort of very preterm infants.

Limitations

HWE was unlikely for the cohort. This implies one of the following: genotyping is flawed, population stratification is present or selection upon the tested genotype has taken place [22]. Our genotyping was performed at the same time as two control series (some 400 and 1,500 controls, respectively), and none of these showed evidence against HWE [11, 23]. Furthermore, we tested a subsample in two different laboratories with two different methods and found no difference in genotypes.

The Danish population is genetically very homogeneous, and in a sensitivity test, ethnic heterogeneity failed to explain the lack of HWE. Thus, selection may be the most likely cause of the deviation from HWE. The study cohort was selected toward survivors, and UGT1A1*28 genotypes increased with decreasing gestational age and increasing mortality. It is possible that fetuses with the UGT1A1*28 genotypes are more prone to be born preterm, but our data may also suggest ex utero selection and an increased chance of survival in preterm infants with UGT1A1*28 genotypes.

As death and BPD/cessation of supplementary oxygen are competing outcomes, an association between UGT1A1*28 genotypes and survival could cause immortal person-time bias in our estimates [24]. A recommended approach to avoid immortal person-time bias is to exclude the immortal time from the denominator [24]. We did so in a test of robustness by only including risk time after 28 days’ postnatal age, and the results were essentially unchanged. In addition, our results also remained essentially unchanged after stratification according to gestational age (a proxy variable for the risk of early death). Accordingly, immortal person-time bias is unlikely to explain our results.

We adjusted for African heritage due to a higher frequency of UGT1A1*28 genotypes and a lower neonatal morbidity in this population [10, 25]. Few infants of African heritage were present in the cohort, and the adjustment made no difference to our results.

Interpretation

The UGT1A1 enzyme metabolizes a variety of other endogenous and exogenous substances apart from bilirubin [10]. Also, the association between UGT1A1*28 genotypes and plasma bilirubin is well established in adults, but no data for preterm infants exist. Thus, it is very possible that metabolites other than bilirubin may play a role in the association between UGT1A1*28 genotypes and preterm respiratory morbidity.

Morris et al. [5] published a large randomized trial of two thresholds of serum bilirubin for phototherapy in very preterm infants. In the secondary analyses, they found that a higher treatment threshold, and thus higher overall bilirubin levels, was associated with a higher risk of BPD. This is in accordance with our findings.

A decreased respiratory drive due to a direct effect on the central nervous system of higher levels of bilirubin may be one potential explanation of these findings. A previous study has shown an association between hyperbilirubinemia and the risk of apnea and bradycardia in preterm infants [26]. Furthermore, analyses from the trial by Morris et al. [5] showed neurotoxic effects from plasma bilirubin levels at higher treatment thresholds.

We found no association between UGT1A1*28 genotypes and the need of rescue surfactant in the very preterm infants. This is in line with data that suggest that UGT1A1 activity is very low in the preterm infant immediately after birth and, therefore, that no effect of the genotype in the first days of life is to be expected [27].

In preterm infants with birth weights of 501–750 g, Morris et al. [5] found that a high phototherapy treatment threshold (a high bilirubin level) was associated with increased survival. This could be in accordance with our observation of an increased frequency of UGT1A1*28 genotypes amongst the most preterm surviving infants if bilirubin is the causative metabolite in our study.

Conclusion

Compared to the common genotype, UGT1A1*28 genotypes were associated with an increased need of oxygen supplementation and risk of BPD in preterm newborns.

Acknowledgment

The study was supported by a grant from the Danish Council for Independent Research (DFF-1331-00297B).
References


16 Andersson S, Petersen J, Brink HT, Ebbees F: The Danish neonatal clinical database is valuable for epidemiologic research in respi- ratory disease in preterm infants. BMC Pedi- atr 2014:14:47.


